• 1
    Tugwell P, Boers M, and the OMERACT Committee. Developing consensus on preliminary core efficacy endpoints for rheumatoid arthritis clinical trials. J Rheumatol 1993; 20: 5556.
  • 2
    Gladman DD, Mease PJ, Krueger G, van der Heidje DM, Antoni C, Helliwell PS, et al. Outcome measures in psoriatic arthritis. J Rheumatol 2005; 32: 22629.
  • 3
    Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 13745.
  • 4
    Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. J Rheumatol 2003; 30: 16778.
  • 5
    Blackmore MG, Gladman DD, Husted J, Long JA, Farewell VT. Measuring health status in psoriatic arthritis: the Health Assessment Questionnaire and its modification. J Rheumatol 1995; 22: 88693.
  • 6
    Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992; 35: 498502.
  • 7
    Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52: 327989.
  • 8
    Antoni CE, Kavanagh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum 2005; 52: 122736.
  • 9
    Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P, et al, for the Treatment of Psoriatic Arthritis Study Group. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2004; 50: 193950.
  • 10
    Wolfe F, Michaud K, Pincus T. Development and validation of the Health Assessment Questionnaire II: a revised version of the Health Assessment Questionnaire. Arthritis Rheum 2004; 50: 3296305.
  • 11
    Husted JA, Gladman DD, Farewell VT, Long JA, Cook RJ. Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis. J Rheumatol 1997; 24: 5117.
  • 12
    Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005; 64: 11507.
  • 13
    Husted JA, Gladman DD, Cook RJ, Farewell VT. Responsiveness of health status instruments to changes in articular status and perceived health in patients with psoriatic arthritis. J Rheumatol 1998; 25: 214655.
  • 14
    Brazier JE, Walters SJ, Nicholl JP, Kohler B. Using the SF-36 and Euroqol on an elderly population. Qual Life Res 1996; 5: 195204.
  • 15
    Hunt SM, McKenna SP. Measuring patients' views of their health: SF-36 misses the mark [letter]. BMJ 1993; 307: 125.
  • 16
    Larson JS. The MOS 36-item short form health survey: a conceptual analysis. Eval Health Prof 1997; 20: 1427.
  • 17
    Bernheim JL. How to get serious answers to the serious question: “How have you been?”: subjective quality of life (QOL) as an individual experiential emergent construct. Bioethics 1999; 13: 27287.
  • 18
    Fries JF, Bruce B, Cella D. The promise of PROMIS: using item response theory to improve assessment of patient-reported outcomes. Clin Exp Rheumatol 2005; 23 Suppl 39: S537.
  • 19
    Waugh RF, Chapman ES. An analysis of dimensionality using factor analysis (true-score theory) and Rasch measurement: what is the difference? Which method is better? J Appl Meas 2005; 6: 8099.
  • 20
    Bond TG, Fox CM. Applying the Rasch model: fundamental measurement in the human sciences. Mahwah (NJ): Lawrence Erlbaum Associates; 2001.
  • 21
    Tennant A, Hillman M, Fear J, Pickering A, Chamberlain MA. Are we making the most of the Stanford Health Assessment Questionnaire? Br J Rheumatol 1996; 35: 5748.
  • 22
    Wolfe F. Which HAQ is best? A comparison of the HAQ, MHAQ and RA-HAQ, a difficult 8 item HAQ (DHAQ), and a rescored 20 item HAQ (HAQ20): analyses in 2,491 rheumatoid arthritis patients following leflunomide initiation. J Rheumatol 2001; 28: 9829.
  • 23
    Singh A, Mease P, Yu H, Chiou CF, Tsuji W. Health Assessment Questionnaire has similar psychometric properties in psoriatic arthritis and rheumatoid arthritis [abstract]. Arthritis Rheum 2005; 52: S403.
  • 24
    Kirwan JR, Reeback JS. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol 1986; 25: 2069.
  • 25
    Ware JE Jr, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 47383.
  • 26
    Linacre JM. WINSTEPS Rasch measurement computer program. Chicago:; 2006.
  • 27
    Lassere M, Wells G, Tugwell P, Edmonds J. Percentile curve reference charts of physical function: rheumatoid arthritis population. J Rheumatol 1995; 22: 12416.
  • 28
    Raczek AE, Ware JE Jr, Bjorner JB, Gandek B, Haley SM, Aaronson NK, et al. Comparison of Rasch and summated rating scales constructed from SF-36 physical functioning items in seven countries: results from the IQOLA project. J Clin Epidemiol 1998; 51: 120314.
  • 29
    McHorney CA. Health status assessment methods for adults: past accomplishments and future challenges. Ann Rev Public Health 1999; 20: 30935.